France Invented Ebola Rapid Detection Method Like Pregnancy Test Bar.

Emergency workers in protective clothing work in a parking lot outside The Pentagon in Washington, D.C. on October 17th.

On that day, The Pentagon

A woman was found sick and vomiting in a parking lot outside the building. It was found that the woman had been to Africa recently.

The Pentagon has closed the parking lot and an entry for further investigation in order to prevent Ebola epidemic.

Reference News Network reported on October 23rd, foreign media said that France's R & D team said in October 21st that they developed a new method of rapid detection of Ebola virus, which is similar to the family pregnancy test method, so that doctors can confirm in 15 minutes whether a suspected patient is infected with Ebola virus.

According to Agence France-Presse reported on October 21st, the French Atomic Energy Commission said in a statement that a highly safe laboratory test has verified this new method.

The rapid detection tool should be pported to countries with Ebola virus before the end of October for clinical trials.

such

It is through detecting the reaction of monoclonal antibodies to Ebola virus in small samples.

A small sample can be a drop of blood, serum or urine.

Regulators have yet to approve such testing tools.

Reported that the French pharmaceutical company Weida Labu company is expected to launch a convenient testing tool eZYSCREEN.

It is similar to a self test pregnancy stick or a pregnancy test strip. A bar appears on the display window, which indicates that the test results are positive.

The French Atomic Energy Commission says the detection tool is easy to operate and does not require any other equipment.

"In less than 15 minutes, it is possible to diagnose whether people with suspected Ebola symptoms really infected the virus.

At present, the method of gene detection is very sensitive, but it needs special equipment, and it takes 2 hours, 15 minutes, 2 hours and 30 minutes to get the results, and it can only be detected in the laboratory. "

According to The Associated Press reported on October 21st, WHO is pushing ahead with the development of the Ebola vaccine. It is hoped that the first batch of two experimental vaccines will be injected from more than twenty thousand front-line medical workers and other personnel in the hardest hit areas of West Africa from January next year.

For the initial response

The World Health Organization, which has been criticized for its ineffective crisis, is helping coordinate the testing of the two most promising test vaccines.

It is reported that only when these vaccines are proved safe in clinical trials in Europe, Africa and the United States, and will trigger sufficient immune response, will they be tested in West Africa.

Mary Gene, a senior official of the World Health Organization, admitted that there are many "uncertainties" and "possibility of failure".

But she briefly introduced a more extensive test than the 6 month scenario, and said that who hopes to release tens of thousands of vaccines in the first few months of next year.

A spokesman for the World Health Organization said later that the Group expects to receive twenty thousand vaccines in January next year, and that it will be achieved in the next few months.

The US financial news network reported on October 21, the researchers said that every Ebola vaccine that was queuing up for testing had defects, including the disappearance of vaccine efficacy in less than a year and the appearance of flu like symptoms in healthy people.

Some vaccines have just started human testing, and testing may detect unknown side effects.

Schneer, who is developing Ebola and rabies vaccine, said: "we should test as many vaccines as possible.

Before extensive vaccination, more clinical data are needed for each vaccine. "

Ben Newman, a virologist at University of Reading in England, said that if the vaccine was injected into healthy people, serious accidental consequences could do more harm than good.

Newman said that for Ebola virus, some vaccines cause the body to produce an immune response that is not accurate against the virus, which may make the virus more susceptible to infection of healthy cells.

The British GlaxoSmithKline Co has begun testing the safety of vaccines.

The company is working with the National Institutes of health and the new link gene company to test a product developed by researchers from the Canadian government.

GlaxoSmithKline will start next year in the African region affected by Ebola in the human efficacy test.